Skip to main content
  • Saved

made a Post

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis - PubMed

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33905962/

doi: 10.1016/j.ctarc.2021.100378. Online ahead of print. 1 Hospital doce de Octubre, Medical Oncology Department Thoracic Cancer and Early Drug Development Unit, Madrid, Spain. Electronic address: sponceaix@gmail.com. 2 Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy. 3 David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Santa Monica, CA, United States.